AstraZeneca is investing $2 billion in Summit Therapeutics to collaborate on cancer drug development, acquiring about 12% of Summit's common stock. The partnership will start clinical trials combining Summit’s ivonescimab with AstraZeneca’s sonesitatug vedotin to treat gastrointestinal cancers. Both companies will share trial costs and retain rights to their own drugs. This move supports AstraZeneca’s strategy to combine antibody-drug conjugates with immunotherapies, following positive results from its gastric cancer trial.
AstraZeneca shares trade at USD 166.15 on Pluang as of Sep 29, 2026 14:01 WIB, showing no change in the last day. The stock holds a market cap of $257.16 billion and a dividend yield of 1.92%. Pluang investors show strong interest, with 98% of orders to buy and a typical hold time of 125 days. This stable trading environment coincides with AstraZeneca's new $2 billion investment in Summit Therapeutics for cancer drug development.
Anthropic's IPO prospectus reveals serious warnings about AI risks, including potential catastrophic harm and rogue behavior from its models. Despite these risks, the company, known for its Claude chatbot, aims for a $2tn valuation with revenue growi...
AstraZeneca PLC has received EU approval for its asthma treatment Trixeo Aerosphere, expanding its market in Respiratory & Immunology. The company leverages mid-single-digit revenue growth into stronger earnings per share gains, driven by its oncolog...
